Scalper1 News
On Friday, hospitals could get a new life-saving antibiotic, and investors could see the first step in the resuscitation of Cubist Pharmaceuticals. Just a couple of years ago Cubist (CBST) was an IBD 50 mainstay, riding the success of Cubicin, a treatment for deadly hospital-based infections. In summer of 2012, the company unveiled an ambitious five-year plan that involved doubling revenue by 2017 through the launch of four new products, which Scalper1 News
Scalper1 News